This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letters  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Medical Ethics  • Cardiovascular System  • Quality of Care  • Patient Safety/ Medical Error  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Hematology/ Hematologic Malignancies  • Anemias  • Hematology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We share many of the concerns regarding the need for proper oversight in conducting and transparency in reporting the results of human studies expressed in the Editorial by Drs Fergusson and McIntyre.¹ We agree with them and with Dr Natanson and colleagues² that some of the large clinical HBOC trials might have been halted if the results of previous animal and human studies showing risk were known. However, we feel that the Editorial did not put into proper perspective the risk associated with allogeneic blood transfusion.

Fergusson and McIntyre introduce their Editorial by stating that there is an "adequate and safe blood supply in North America and Europe" and end by stating that "[g]iven the safety of the blood supply . . . it does not seem prudent to study use of HBOCs in elective surgical populations."¹ Although these statements are true for safety from transmission of common blood-borne pathogens and . . . [Full Text of this Article]

Babak Sarani, MD
babak.sarani@uphs.upenn.edu

Vicente Gracias, MD
Department of Surgery
Division of Traumatology and Surgical Critical Care
University of Pennsylvania
Philadelphia

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death: A Meta-analysis
Charles Natanson, Steven J. Kern, Peter Lurie, Steven M. Banks, and Sidney M. Wolfe
JAMA. 2008;299(19):2304-2312.
ABSTRACT | FULL TEXT  

RELATED LETTERS

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Lewis J. Levien, Richard E. Hodgson, and Michael F. M. James
JAMA. 2008;300(11):1295.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Peter E. Keipert, Christina Olofsson, and Robert M. Winslow
JAMA. 2008;300(11):1295-1296.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Roger J. Lewis and Norman Fost
JAMA. 2008;300(11):1296.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Aryeh Shander, Mazyar Javidroozi, and Gary Thompson
JAMA. 2008;300(11):1296-1297.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Angela Sauaia, Ernest E. Moore, and Anirban Banerjee
JAMA. 2008;300(11):1297.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death—Reply
Charles Natanson, Peter Lurie, and Sidney M. Wolfe
JAMA. 2008;300(11):1298-1299.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death—Reply
Dean Fergusson and Lauralyn McIntyre
JAMA. 2008;300(11):1299.
EXTRACT | FULL TEXT